GlassScriptPhysician profile
Samara Pollock
NPI 1184201295
$1,200.05
in general payments reported to CMS, 2019-2025
11 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.86 · 2023: $316 · 2024: $157 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.19 |
| Education | $243.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $278.67 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $219.96 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $207.12 | 2023-2025 | |
| Janssen Biotech, INC. | $171.00 | 2024-2025 | Tremfya |
| Genzyme Corporation | $95.86 | 2022 | |
| Abbvie INC. | $75.42 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.03 | 2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $34.20 | 2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $21.85 | 2023 | Ycanth |
| Galderma Laboratories, L.P. | $20.24 | 2025 | Nemluvio |
| Organon LLC | $2.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samara Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.